Bausch & Lomb Corp executive Frederick Munsch, SVP, Controller and CAO, reported acquiring 12,498 common shares at a price of $0.00 per share. These shares relate to performance stock units granted on March 1, 2023 that satisfied performance conditions as of February 18, 2026.
The earned PSUs will vest on March 1, 2026, generally contingent on Munsch’s continued employment through that date. Following this award, his directly held stake increased to 90,231 common shares.
Bonnefoy Luc reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp President, Surgical, Luc Bonnefoy reported an equity award involving 10,202 common shares of the company. These shares relate to performance stock units granted on March 1, 2023 that met their performance conditions as of February 18, 2026. The earned units are scheduled to vest on March 1, 2026, generally conditioned on his continued employment, bringing his reported direct holdings to 87,564 common shares.
Bausch & Lomb Corp EVP of R&D and CMO Yehia Hashad reported an equity award acquisition. He earned 29,406 common shares underlying performance stock units originally granted on March 1, 2023 after the award satisfied its performance conditions as of February 18, 2026.
The earned PSUs will convert into common shares and vest on March 1, 2026, generally contingent on his continued employment through that date. Following this award, Hashad’s direct holdings total 163,860 common shares, aligning his compensation more closely with the company’s long-term performance.
Bausch & Lomb Corp EVP and CFO Sam Eldessouky reported an equity award tied to performance. He acquired 70,578 common shares underlying performance stock units that met performance conditions as of February 18, 2026, from a grant originally made on March 1, 2023.
The earned performance stock units will vest on March 1, 2026, generally contingent on his continued employment through that date. Following this non-cash grant/award acquisition, his directly owned common shares total 391,394.
Bausch + Lomb reports 2025 total revenue of $5,101 million, up from $4,791 million in 2024 and $4,146 million in 2023, reflecting steady growth across its global eye health portfolio.
Vision Care generated $2,923 million, or 57% of revenue, Pharmaceuticals $1,284 million (25%) and Surgical $894 million (18%). The company sells about 400 products in roughly 100 countries and employs about 13,000 people.
Bausch + Lomb remains a majority-owned subsidiary of Bausch Health Companies Inc., which held about 88% of common shares as of February 11, 2026, and BHC continues to evaluate a potential separation of the eye health business, with no assurance it will be completed.
Bausch + Lomb reported solid growth for 2025 but remained unprofitable. Fourth-quarter revenue reached $1.405 billion, up 10% year over year, with full-year revenue of $5.101 billion, up 6%. All three segments – Vision Care, Surgical and Pharmaceuticals – grew mid- to high-single digits for the year.
Despite this, the company posted a Q4 GAAP net loss of $58 million and a full-year net loss of $360 million. Profitability looked stronger on a non-GAAP basis: Q4 adjusted EBITDA rose to $326 million and full-year adjusted EBITDA was $858 million. Management guided 2026 revenue to $5.375–$5.475 billion with $1.0–$1.05 billion in adjusted EBITDA excluding acquired IPR&D, implying continued growth and margin focus.
Bausch & Lomb Corp director Steven H. Collis filed an initial insider ownership report indicating that he does not beneficially own any company securities. The Form 3 confirms his role as a director of Bausch & Lomb while stating in the remarks that no securities are beneficially owned. A power of attorney is on file, authorizing an attorney-in-fact to sign on his behalf.
Bausch & Lomb Corp director reports no share ownership
Bausch & Lomb Corp (BLCO) director Alfonso Eduardo filed an initial ownership report stating that no securities of the company are beneficially owned. This Form 3 confirms that, as of the reported date, he does not hold Bausch & Lomb common stock or derivative securities in either a direct or indirect capacity.
Bausch + Lomb Corporation amended its existing credit agreement by arranging a new $2,802,125,000 tranche of term loans maturing in 2031, called the Replacement Term Loans. The proceeds were used to refinance its outstanding term B loans due 2031 and term B loans due 2028, effectively extending the earlier 2028 maturity to 2031.
The Replacement Term Loans amortize at 1.00% per year, with the first installment due on June 30, 2026. The applicable margin is 3.75% per year for loans referencing term SOFR and 2.75% per year for loans referencing the alternate base rate, representing margin reductions of 0.50% and 0.25%, respectively, compared with the prior term loans.
Bausch + Lomb Corporation filed an amended current report to update board committee assignments for two recently appointed directors. The company had previously disclosed that Eduardo C. Alfonso, MD, and Steven H. Collis would join the board effective January 1, 2026.
The amendment states that, effective January 1, 2026, Dr. Alfonso will serve on the Science and Technology Committee and Mr. Collis will serve on the Talent and Compensation Committee. These changes clarify how the new directors will participate in the company’s governance structure.